Key cost drivers of pharmaceutical clinical trials in the United States

  title={Key cost drivers of pharmaceutical clinical trials in the United States},
  author={Aylin Sertkaya and Hui-Hsing Wong and Amber Jessup and Trinidad Beleche},
  journal={Clinical Trials},
  pages={117 - 126}
Background: The increasing cost of clinical research has significant implications for public health, as it affects drug companies’ willingness to undertake clinical trials, which in turn limits patient access to novel treatments. [] Key Method We evaluated per-study costs across therapeutic areas by aggregating detailed (per patient and per site) cost information. We also compared average expenditures on cost drivers with the use of weighted mean and standard deviation statistics. Results: Therapeutic area…

Figures and Tables from this paper

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study
The estimated costs of the pivotal clinical trials supporting the approval of 101 new therapeutic agents approved by the US Food and Drug Administration from 2015 to 2017 are a cross-sectional study of the likely costs of clinical trials to be conducted by contract research organisations.
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016
The highest-cost trials were those in which the new agent had to be proved to be noninferior with clinical benefit end points compared with an agent already available or those that required larger patient populations to achieve statistical power to document smaller treatment effects or accrue infrequently occurring end points.
Funding of Clinical Trials and Reported Drug Efficacy∗
The effect of financial sponsorship on reported drug efficacy is estimated, leveraging the insight that the exact same sets of drugs are often compared in different randomized control trials conducted by parties with different financial interests.
Future of risk based monitoring in clinical trials
The future of risk based approach towards managing clinical trials is going to be very different from what the authors see now with the changing landscape of drug development which includes novel therapies like gene therapy, remote/decentralized trials, growing use of wearable technologies, esource, electronic health record/electronic medical records interoperability, implementation of artificial intelligence and machine learning algorithms.
Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results
Research and development (R&D) costs factor into considerations of the tradeoffs between prices, intellectual property protection, and incentivizing innovation, all of which can have implications for
Registry-based trials: a potential model for cost savings?
A practical tool that investigators could use across disciplines to estimate the ranges of potential cost differences associated with implementing registry-based trials versus standard clinical trials is built.
Mapping the Cohesion and Synergy in Clinical Research Sites
Background and Introduction Clinical Research is a combination of many diverse and dedicated professional talents. A clinical research site usually comprises of coordinators, researchers, physicians,
The value of randomized trials for efficacy in oncology: Lessons from off-label prescribing
This paper investigates the role of efficacy evidence produced in randomized controlled trials (RCTs) on demand for cancer drugs. I use the unique setting of off-label prescribing, where it is
Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?
Administrative data were more complete than trial data for hospital encounters, a key cost driver in economic analysis, and demonstrates the potential of administrative data to relieve the burden of collecting key data in cancer trials, which represents a considerable effort and expense.
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
New funding mechanisms to support clinical research may become more important in the future but the unresolved issues identified in the current study warrant further exploration.


The costs of conducting clinical research.
The time required for nontreatment trial activities is considerable, and the associated costs are substantial, according to the results of a mock phase III clinical research trial.
Sensible approaches for reducing clinical trial costs
It is suggested that it is possible to reduce substantially the cost of large-scale clinical trials without compromising the scientific validity of their results and could free billions of dollars annually for additional clinical studies.
Assessing the Impact of Protocol Design Changes on Clinical Trial Performance
The results of this study indicate that the number of unique procedures and the frequency of procedures per protocol have increased at the annual rate of 6.5% and 8.7%, respectively, during the time period measured, and implications for simplifying protocol designs and minimizing negative effects on study conduct performance are discussed.
The price of innovation: new estimates of drug development costs.
PhRMA BioResearch Monitoring Committee Perspective on Acceptable Approaches for Clinical Trial Monitoring
The current thinking of the PhRMA BioResearch Monitoring Committee on acceptable approaches to clinical trial monitoring is provided, taking advantage of risk-based decision making and modem technological tools.
Estimating the cost of new drug development: is it really 802 million dollars?
This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues, using their published cost estimates along with information on success rates and durations from a publicly available data set, to estimate the cost per new drug between 1989 and 2002.
Impediments to Clinical Research in the United States
Clinical trials are essential to the evaluation of promising scientific discoveries, but they are becoming unsustainably burdensome, threatening to deprive patients and health‐care providers of new
Risk-Based Source Data Verification Approaches: Pros and Cons
This article evaluates the FDA-supported risk-based approach to SDV and provides a proposal on how to modify the SDV process without undermining the validity and integrity of the trial data.
New Governance Mechanisms to Optimize Protocol Design
A qualitative in-depth assessment of 10 major pharmaceutical companies that have implemented new governance mechanisms designed to evaluate protocol feasibility and simplify design before final protocol approval since 2009 is conducted.